Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 171

1.

Implementation of flow cytometry in the diagnostic work-up of myelodysplastic syndromes in a multicenter approach: report from the Dutch Working Party on Flow Cytometry in MDS.

Westers TM, van der Velden VH, Alhan C, Bekkema R, Bijkerk A, Brooimans RA, Cali C, Dräger AM, de Haas V, Homburg C, de Jong A, Kuiper-Kramer PE, Leenders M, Lommerse I, te Marvelde JG, van der Molen-Sinke JK, Moshaver B, Mulder AB, Preijers FW, Schindhelm RK, van der Sluijs A, van Wering ER, Westra AH, van de Loosdrecht AA; Working Party on Flow Cytometry in MDS of Dutch Society of Cytometry (NVC).

Leuk Res. 2012 Apr;36(4):422-30. doi: 10.1016/j.leukres.2011.09.015. Epub 2011 Oct 6.

PMID:
21982641
2.

Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.

Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, Reinhardt D, Hollink IH, Arentsen-Peters ST, van Wering ER, Kaspers GJ, Cloos J, de Bont ES, Cayuela JM, Baruchel A, Meyer C, Marschalek R, Trka J, Stary J, Beverloo HB, Pieters R, Zwaan CM, den Boer ML.

Haematologica. 2011 Feb;96(2):221-30. doi: 10.3324/haematol.2010.029660. Epub 2010 Oct 22.

3.

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome.

Göhring G, Michalova K, Beverloo HB, Betts D, Harbott J, Haas OA, Kerndrup G, Sainati L, Bergstraesser E, Hasle H, Stary J, Trebo M, van den Heuvel-Eibrink MM, Zecca M, van Wering ER, Fischer A, Noellke P, Strahm B, Locatelli F, Niemeyer CM, Schlegelberger B.

Blood. 2010 Nov 11;116(19):3766-9. doi: 10.1182/blood-2010-04-280313. Epub 2010 Aug 27.

4.

Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.

van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ.

Leukemia. 2010 Sep;24(9):1599-606. doi: 10.1038/leu.2010.153. Epub 2010 Jul 29.

PMID:
20668473
5.

Preemptive alloimmune intervention in high-risk pediatric acute lymphoblastic leukemia patients guided by minimal residual disease level before stem cell transplantation.

Lankester AC, Bierings MB, van Wering ER, Wijkhuijs AJ, de Weger RA, Wijnen JT, Vossen JM, Versluys B, Egeler RM, van Tol MJ, Putter H, Révész T, van Dongen JJ, van der Velden VH, Schilham MW.

Leukemia. 2010 Aug;24(8):1462-9. doi: 10.1038/leu.2010.133. Epub 2010 Jun 10.

PMID:
20535148
6.

EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.

Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM.

Leukemia. 2010 May;24(5):942-9. doi: 10.1038/leu.2010.47. Epub 2010 Apr 1.

PMID:
20357826
7.

Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique.

Balgobind BV, Hollink IH, Reinhardt D, van Wering ER, de Graaf SS, Baruchel A, Stary J, Beverloo HB, de Greef GE, Pieters R, Zwaan CM, van den Heuvel-Eibrink MM.

Eur J Cancer. 2010 Jul;46(10):1892-9. doi: 10.1016/j.ejca.2010.02.019. Epub 2010 Mar 16.

PMID:
20233657
8.

Genome-wide expression analysis of paired diagnosis-relapse samples in ALL indicates involvement of pathways related to DNA replication, cell cycle and DNA repair, independent of immune phenotype.

Staal FJ, de Ridder D, Szczepanski T, Schonewille T, van der Linden EC, van Wering ER, van der Velden VH, van Dongen JJ.

Leukemia. 2010 Mar;24(3):491-9. doi: 10.1038/leu.2009.286. Epub 2010 Jan 14.

PMID:
20072147
9.

Acquisition of genome-wide copy number alterations in monozygotic twins with acute lymphoblastic leukemia.

Bateman CM, Colman SM, Chaplin T, Young BD, Eden TO, Bhakta M, Gratias EJ, van Wering ER, Cazzaniga G, Harrison CJ, Hain R, Ancliff P, Ford AM, Kearney L, Greaves M.

Blood. 2010 Apr 29;115(17):3553-8. doi: 10.1182/blood-2009-10-251413. Epub 2010 Jan 8.

PMID:
20061556
10.

Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).

Veerman AJ, Kamps WA, van den Berg H, van den Berg E, Bökkerink JP, Bruin MC, van den Heuvel-Eibrink MM, Korbijn CM, Korthof ET, van der Pal K, Stijnen T, van Weel Sipman MH, van Weerden JF, van Wering ER, van der Does-van den Berg A; Dutch Childhood Oncology Group.

Lancet Oncol. 2009 Oct;10(10):957-66. doi: 10.1016/S1470-2045(09)70228-1. Epub 2009 Sep 9.

PMID:
19747876
11.

CD34 expression is associated with poor survival in pediatric T-cell acute lymphoblastic leukemia.

van Grotel M, van den Heuvel-Eibrink MM, van Wering ER, van Noesel MM, Kamps WA, Veerman AJ, Pieters R, Meijerink JP.

Pediatr Blood Cancer. 2008 Dec;51(6):737-40. doi: 10.1002/pbc.21707.

PMID:
18683236
12.

T-cell receptor Vbeta CDR3 oligoclonality frequently occurs in childhood refractory cytopenia (MDS-RC) and severe aplastic anemia.

de Vries AC, Langerak AW, Verhaaf B, Niemeyer CM, Stary J, Schmiegelow K, van Wering ER, Zwaan CM, Beishuizen A, Pieters R, van den Heuvel-Eibrink MM.

Leukemia. 2008 Jun;22(6):1170-4. doi: 10.1038/leu.2008.23. Epub 2008 Mar 6.

PMID:
18323803
13.

The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia.

Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP.

Blood. 2008 May 1;111(9):4668-80. doi: 10.1182/blood-2007-09-111872. Epub 2008 Feb 25.

14.

Cooperative genetic defects in TLX3 rearranged pediatric T-ALL.

Van Vlierberghe P, Homminga I, Zuurbier L, Gladdines-Buijs J, van Wering ER, Horstmann M, Beverloo HB, Pieters R, Meijerink JP.

Leukemia. 2008 Apr;22(4):762-70. doi: 10.1038/sj.leu.2405082. Epub 2008 Jan 10.

PMID:
18185524
15.

Leukemia-associated NF1 inactivation in patients with pediatric T-ALL and AML lacking evidence for neurofibromatosis.

Balgobind BV, Van Vlierberghe P, van den Ouweland AM, Beverloo HB, Terlouw-Kromosoeto JN, van Wering ER, Reinhardt D, Horstmann M, Kaspers GJ, Pieters R, Zwaan CM, Van den Heuvel-Eibrink MM, Meijerink JP.

Blood. 2008 Apr 15;111(8):4322-8. doi: 10.1182/blood-2007-06-095075. Epub 2008 Jan 2.

PMID:
18172006
16.

Monoallelic or biallelic LMO2 expression in relation to the LMO2 rearrangement status in pediatric T-cell acute lymphoblastic leukemia.

Van Vlierberghe P, Beverloo HB, Buijs-Gladdines J, van Wering ER, Horstmann M, Pieters R, Meijerink JP.

Leukemia. 2008 Jul;22(7):1434-7. Epub 2007 Dec 13. No abstract available.

PMID:
18079736
17.

Role of mutation independent constitutive activation of FLT3 in juvenile myelomonocytic leukemia.

de Vries AC, Stam RW, Schneider P, Niemeyer CM, van Wering ER, Haas OA, Kratz CP, den Boer ML, Pieters R, van den Heuvel-Eibrink MM.

Haematologica. 2007 Nov;92(11):1557-60.

18.

BMI1 as oncogenic candidate in a novel TCRB-associated chromosomal aberration in a patient with TCRgammadelta+ T-cell acute lymphoblastic leukemia.

Larmonie NS, Dik WA, Beverloo HB, van Wering ER, van Dongen JJ, Langerak AW.

Leukemia. 2008 Jun;22(6):1266-7. Epub 2007 Nov 8. No abstract available.

PMID:
17989714
19.

Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences.

van Grotel M, Meijerink JP, van Wering ER, Langerak AW, Beverloo HB, Buijs-Gladdines JG, Burger NB, Passier M, van Lieshout EM, Kamps WA, Veerman AJ, van Noesel MM, Pieters R.

Leukemia. 2008 Jan;22(1):124-31. Epub 2007 Oct 11.

PMID:
17928886
20.

The outcome of molecular-cytogenetic subgroups in pediatric T-cell acute lymphoblastic leukemia: a retrospective study of patients treated according to DCOG or COALL protocols.

van Grotel M, Meijerink JP, Beverloo HB, Langerak AW, Buys-Gladdines JG, Schneider P, Poulsen TS, den Boer ML, Horstmann M, Kamps WA, Veerman AJ, van Wering ER, van Noesel MM, Pieters R.

Haematologica. 2006 Sep;91(9):1212-21.

21.

The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.

Van Vlierberghe P, van Grotel M, Beverloo HB, Lee C, Helgason T, Buijs-Gladdines J, Passier M, van Wering ER, Veerman AJ, Kamps WA, Meijerink JP, Pieters R.

Blood. 2006 Nov 15;108(10):3520-9. Epub 2006 Jul 27.

PMID:
16873670
22.

Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia.

Meier M, den Boer ML, Meijerink JP, Broekhuis MJ, Passier MM, van Wering ER, Janka-Schaub GE, Pieters R.

Leukemia. 2006 Aug;20(8):1377-84. Epub 2006 Jun 22.

PMID:
16791269
23.

Prognostic significance of blasts in the cerebrospinal fluid without pleiocytosis or a traumatic lumbar puncture in children with acute lymphoblastic leukemia: experience of the Dutch Childhood Oncology Group.

Dutch Childhood Oncology Group, te Loo DM, Kamps WA, van der Does-van den Berg A, van Wering ER, de Graaf SS.

J Clin Oncol. 2006 May 20;24(15):2332-6.

PMID:
16710032
24.

A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia.

van Vlierberghe P, Meijerink JP, Lee C, Ferrando AA, Look AT, van Wering ER, Beverloo HB, Aster JC, Pieters R.

Leukemia. 2006 Jul;20(7):1245-53. Epub 2006 May 4.

PMID:
16673019
25.

High incidence of t(7;12)(q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9.

von Bergh AR, van Drunen E, van Wering ER, van Zutven LJ, Hainmann I, Lönnerholm G, Meijerink JP, Pieters R, Beverloo HB.

Genes Chromosomes Cancer. 2006 Aug;45(8):731-9.

PMID:
16646086
26.
27.

Incidence of additional genetic changes in the TEL and AML1 genes in DCOG and COALL-treated t(12;21)-positive pediatric ALL, and their relation with drug sensitivity and clinical outcome.

Stams WA, Beverloo HB, den Boer ML, de Menezes RX, Stigter RL, van Drunen E, Ramakers-van-Woerden NL, Loonen AH, van Wering ER, Janka-Schaub GE, Pieters R.

Leukemia. 2006 Mar;20(3):410-6.

PMID:
16424874
28.

Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects.

Brouwer C, Vermunt-de Koning DG, Trueworthy RC, Ter Riet PG, Duley JA, Trijbels FJ, Hoogerbrugge PM, Bökkerink JP, van Wering ER, De Abreu RA.

Pediatr Blood Cancer. 2006 Apr;46(4):434-8.

PMID:
16333815
29.

The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.

Hubeek I, Stam RW, Peters GJ, Broekhuizen R, Meijerink JP, van Wering ER, Gibson BE, Creutzig U, Zwaan CM, Cloos J, Kuik DJ, Pieters R, Kaspers GJ.

Br J Cancer. 2005 Dec 12;93(12):1388-94.

30.

Effect of the histone deacetylase inhibitor depsipeptide on B-cell differentiation in both TEL-AML1-positive and negative childhood acute lymphoblastic leukemia.

Stams WA, den Boer ML, Beverloo HB, Kazemier KM, van Wering ER, Janka-Schaub GE, Pieters R.

Haematologica. 2005 Dec;90(12):1697-9.

31.

Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias.

Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering ER, Beverloo HB, Pieters R.

Blood. 2005 Dec 15;106(13):4414-5. No abstract available.

PMID:
16326981
32.

Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.

Pession A, Valsecchi MG, Masera G, Kamps WA, Magyarosy E, Rizzari C, van Wering ER, Lo Nigro L, van der Does A, Locatelli F, Basso G, Aricò M.

J Clin Oncol. 2005 Oct 1;23(28):7161-7.

PMID:
16192600
33.

Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

Meier M, den Boer ML, Hall AG, Irving JA, Passier M, Minto L, van Wering ER, Janka-Schaub GE, Pieters R.

Leukemia. 2005 Nov;19(11):1887-95.

PMID:
16167060
34.

Genetic variations in the glucocorticoid receptor gene are not related to glucocorticoid resistance in childhood acute lymphoblastic leukemia.

Tissing WJ, Meijerink JP, den Boer ML, Brinkhof B, van Rossum EF, van Wering ER, Koper JW, Sonneveld P, Pieters R.

Clin Cancer Res. 2005 Aug 15;11(16):6050-6.

35.

Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.

Kardos G, Zwaan CM, Kaspers GJ, de-Graaf SS, de Bont ES, Postma A, Bökkerink JP, Weening RS, van der Does-van den Berg A, van Wering ER, Korbijn C, Hählen K.

Leukemia. 2005 Dec;19(12):2063-71.

PMID:
16107896
36.

Immunophenotypic modulation in childhood precursor-B-ALL can be mimicked in vitro and is related to the induction of cell death.

van der Sluijs-Gelling AJ, van der Velden VH, Roeffen ET, Veerman AJ, van Wering ER.

Leukemia. 2005 Oct;19(10):1845-7. No abstract available.

PMID:
16107891
37.

Reply to Gaipa et Al.

van der Sluijs-Gelling AJ, van der Velden VH, Roeffen ET, Veerman AJ, van Wering ER.

Leukemia. 2005 Oct;19(10):1858. No abstract available.

PMID:
16107890
38.

Role of 5'-nucleotidase in thiopurine metabolism: enzyme kinetic profile and association with thio-GMP levels in patients with acute lymphoblastic leukemia during 6-mercaptopurine treatment.

Brouwer C, Vogels-Mentink TM, Keizer-Garritsen JJ, Trijbels FJ, Bökkerink JP, Hoogerbrugge PM, van Wering ER, Veerman AJ, De Abreu RA.

Clin Chim Acta. 2005 Nov;361(1-2):95-103.

PMID:
15990089
39.

Immunophenotypic cell lineage and in vitro cellular drug resistance in childhood relapsed acute lymphoblastic leukaemia.

Kaspers GJ, Wijnands JJ, Hartmann R, Huismans L, Loonen AH, Stackelberg A, Henze G, Pieters R, Hählen K, Van Wering ER, Veerman AJ.

Eur J Cancer. 2005 Jun;41(9):1300-3.

PMID:
15869873
40.

Evaluation of dysplastic features in myelodysplastic syndromes: experience from the morphology group of the European Working Group of MDS in Childhood (EWOG-MDS).

Cantù Rajnoldi A, Fenu S, Kerndrup G, van Wering ER, Niemeyer CM, Baumann I; European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS).

Ann Hematol. 2005 Jul;84(7):429-33. Epub 2005 Apr 19.

PMID:
15838669
41.

Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.

Stams WA, den Boer ML, Beverloo HB, Meijerink JP, van Wering ER, Janka-Schaub GE, Pieters R.

Clin Cancer Res. 2005 Apr 15;11(8):2974-80.

42.

Three-color flowcytometric analysis of mature and immature hematological malignancies. A guideline of the Dutch Foundation for Immunophenotyping of Hematological Malignancies (SIHON).

van Wering ER, van Lochem EG, Leenders M, van der Sluijs-Gelling AJ, Wind H, Gratama JW, Kraan J, Preijers FW.

J Biol Regul Homeost Agents. 2004 Jul-Dec;18(3-4):313-26.

PMID:
15786698
43.

Thiopurine methyltransferase in acute lymphoblastic leukaemia: biochemical and molecular biological aspects.

Brouwer C, De Abreu RA, Keizer-Garritsen JJ, Lambooy LH, Ament K, ter Riet PG, van Wering ER, Trijbels FJ, Veerman AJ, Hoogerbrugge PM, Bökkerink JP.

Eur J Cancer. 2005 Mar;41(4):613-23. Epub 2005 Jan 20.

PMID:
15737567
44.

Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia.

Stams WA, den Boer ML, Holleman A, Appel IM, Beverloo HB, van Wering ER, Janka-Schaub GE, Evans WE, Pieters R.

Blood. 2005 Jun 1;105(11):4223-5. Epub 2005 Feb 17.

PMID:
15718422
45.

Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.

Hubeek I, Peters GJ, Broekhuizen AJ, Talianidis I, Schouten van Meeteren AY, van Wering ER, Gibson B, Creutzig U, Kaspers GJ.

Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(8-9):1351-6.

PMID:
15571257
46.

Upregulation of asparagine synthetase and cell cycle arrest in t(12;21)-positive ALL.

Stams WA, den Boer ML, Beverloo HB, van Wering ER, Pieters R.

Leukemia. 2005 Feb;19(2):318-9; author reply 319-21. No abstract available.

PMID:
15526023
47.

Detection of minimal residual disease in acute leukemia.

van der Velden VH, Boeckx N, van Wering ER, van Dongen JJ.

J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):146-54. Review.

PMID:
15471219
48.

TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse.

van der Velden VH, Brüggemann M, Hoogeveen PG, de Bie M, Hart PG, Raff T, Pfeifer H, Lüschen S, Szczepański T, van Wering ER, Kneba M, van Dongen JJ.

Leukemia. 2004 Dec;18(12):1971-80.

PMID:
15470492
49.

Myelodysplastic features in Griscelli syndrome.

Dolman KM, Révész T, Niemeyer CM, van Wering ER, de Saint Basile G, Canninga M, Bierings MB, Wulffraat NM.

J Pediatr Hematol Oncol. 2004 May;26(5):275-6. No abstract available.

PMID:
15111776
50.

Acute lymphoblastic leukemia followed by a clonally-unrelated EBV-positive non-Hodgkin lymphoma and a clonally-related myelomonocytic leukemia cutis.

Szczepański T, de Vaan GA, Beishuizen A, Bogman J, Jansen MW, van Wering ER, van Dongen JJ.

Pediatr Blood Cancer. 2004 Apr;42(4):343-9.

PMID:
14966831

Supplemental Content

Loading ...
Support Center